Curr Opin Rheumatol. 1994 May;6(3):273-80. doi: 10.1097/00002281-199405000-00005.


Despite the continuing debate about the risks and benefits of glucocorticoid, their central role in the therapeutic armamentarium remains undisputed. Studies continue to unravel the complexity of their biologic effects on gene transcription, and careful clinical observation refines their therapeutic use. Although cloaked in controversy, some recent highlights include the possibility that high-dose intravenous methylprednisolone may affect the development of multiple sclerosis, the suggestion that prednisone may have little efficacy in the management of high-risk pregnancy in patients with antiphospholipid antibodies, and several observations that administration of calcium and vitamin D prevents bone loss in patients receiving steroids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Bone Density / drug effects
  • Drug Administration Routes
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use*
  • Humans
  • Mice
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Prednisone / therapeutic use*
  • Pregnenediones / therapeutic use
  • Rheumatic Diseases / drug therapy*


  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Pregnenediones
  • deflazacort
  • Prednisone